DNLI Denali Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DNLI

Price (delayed)

$30.93

Market cap

$3.8B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.34

Enterprise value

$3.76B

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing ...

Highlights
Denali Therapeutics's debt has decreased by 7% YoY
The EPS has increased by 2.1% from the previous quarter
The quick ratio has dropped by 89% year-on-year but it has grown by 23% since the previous quarter
Denali Therapeutics's gross profit has shrunk by 76% YoY but it has surged by 70% QoQ
Denali Therapeutics's equity has decreased by 17% YoY and by 4.6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.denalitherapeutics.com
Peers: MRVI MGTX NBIX

Key stats

What are the main financial stats of DNLI
Market
Shares outstanding
122.95M
Market cap
$3.8B
Enterprise value
$3.76B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.14
Price to sales (P/S)
45.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
45.37
Earnings
Revenue
$82.88M
EBIT
-$286.34M
EBITDA
-$277.77M
Free cash flow
-$243M
Per share
EPS
-$2.34
Free cash flow per share
-$1.98
Book value per share
$7.47
Revenue per share
$0.68
TBVPS
$10.77
Balance sheet
Total assets
$1.32B
Total liabilities
$402.93M
Debt
$62.75M
Equity
$917.93M
Working capital
$647.2M
Liquidity
Debt to equity
0.07
Current ratio
2.9
Quick ratio
2.81
Net debt/EBITDA
0.15
Margins
EBITDA margin
-335.2%
Gross margin
100%
Net margin
-344.8%
Operating margin
-351.1%
Efficiency
Return on assets
-20.1%
Return on equity
-28.8%
Return on invested capital
-29.8%
Return on capital employed
-29.2%
Return on sales
-345.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DNLI stock price

How has the Denali Therapeutics stock price performed over time
Intraday
2.45%
1 week
29.41%
1 month
33.03%
1 year
-57.88%
YTD
-30.65%
QTD
-3.85%

Financial performance

How have Denali Therapeutics's revenue and profit performed over time
Revenue
$82.88M
Gross profit
$82.88M
Operating income
-$291.03M
Net income
-$285.76M
Gross margin
100%
Net margin
-344.8%
Denali Therapeutics's gross profit has shrunk by 76% YoY but it has surged by 70% QoQ
DNLI's revenue has dropped by 76% year-on-year but it has soared by 70% since the previous quarter
Denali Therapeutics's net margin has increased by 42% from the previous quarter
DNLI's operating margin is up by 42% since the previous quarter

Growth

What is Denali Therapeutics's growth rate over time

Valuation

What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
4.14
P/S
45.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
45.37
The EPS has increased by 2.1% from the previous quarter
DNLI's price to book (P/B) is 33% less than its last 4 quarters average of 6.2 and 14% less than its 5-year quarterly average of 4.8
Denali Therapeutics's equity has decreased by 17% YoY and by 4.6% QoQ
The stock's price to sales (P/S) is 83% less than its 5-year quarterly average of 273.4 and 10% less than its last 4 quarters average of 50.8
DNLI's revenue has dropped by 76% year-on-year but it has soared by 70% since the previous quarter

Efficiency

How efficient is Denali Therapeutics business performance
The ROS has increased by 42% from the previous quarter
The return on equity has declined by 2.9% since the previous quarter
The return on invested capital has declined by 3.1% since the previous quarter
The return on assets has declined by 2% since the previous quarter

Dividends

What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNLI.

Financial health

How did Denali Therapeutics financials performed over time
The current ratio has plunged by 89% YoY but it has grown by 22% from the previous quarter
The quick ratio has dropped by 89% year-on-year but it has grown by 23% since the previous quarter
Denali Therapeutics's debt is 93% less than its equity
DNLI's debt to equity is up by 17% year-on-year
Denali Therapeutics's equity has decreased by 17% YoY and by 4.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.